It has been more than 7 years since the commercial introduction of highly successful
vaccines protecting against high‐risk human papillomavirus (HPV) subtypes and the …

'High-risk'genotypes of the human papillomavirus (HPV), most commonly HPV genotype 16,
are the primary etiologic agents of cervical cancer. Indeed HPV DNA is detected in 99% of …

As cervical cancer is causally associated with 14 high-risk types of human papillomavirus
(HPV), a successful HPV vaccine will have a major impact on this disease. Although some …

Persistent infection by 'high risk'genotypes of human papilloma virus (HPV) is necessary but
not sufficient for the development of over 98% of cervical cancers. Thus the development of …

Cervical cancer is a leading cause of cancer related mortality in women, particularly in
developing countries. As a result of several recent advances in molecular biology, the …

The identification of human papillomavirus (HPV) as a cause of cervical cancer and its
precursor lesions indicates that HPV vaccines can potentially be used to prevent or treat …

Human papillomavirus (HPV) infection causes virtually all cases of cervical cancer, the
second most common cause of death from cancer among women worldwide. This Review …

Cervical cancer is the second largest cause of cancer-related death in women worldwide,
and it occurs following persistent infection, sometimes for decades, with a specific subset of …

Recent clinical trials in young women have shown that subunit vaccines based on human
papillomavirus (HPV) 16 and HPV18 L1 virus-like particles are∼ 100% effective in short …

Human papillomavirus (HPV) is causally associated with 5% of cancers, including cancers
of the cervix, penis, vulva, vagina, anus and oropharynx. The most carcinogenic HPV is HPV …